Alnylam and CAMP4 partner to identify new targets to treat a rare liver disease

Liver
Alnylam and CAMP4 Therapeutics are partnering with a focus on identifying druggable targets for possible treatments of a rare liver disease. (Database Center for Life Science/CC BY-SA 2.1)

Alnylam Pharmaceuticals and CAMP4 Therapeutics, a bioinformatics startup, are partnering with a focus on identifying druggable targets for possible treatments of a rare disease of the liver.

The deal pairs Alnylam’s RNAi therapeutics expertise with CAMP4’s platform that decodes the physical structures used to unlock and turn on or off the expression of individual genes that can cause a disease.

Under terms of the deal, CAMP4 will get an undisclosed upfront payment from Alnylam, with additional milestone payments. CAMP4 could receive additional payments dependent on development, regulatory approval and sales milestones and well as royalties on products developed.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Our Gene Circuitry Platform is yielding the first-ever, comprehensive and dynamic understanding of the Cellular Operating System used by human liver cells to regulate the activation of genes and is applicable to any disease-associated genes in the liver,” Josh Mandel-Brehm, CAMP4’s chief executive, said in a statement. "We look forward to applying this knowledge to elucidate the optimal targets Alnylam can explore for potential RNAi intervention for a disease where there are currently no available treatment options.”

CAMP4, which was formed in 2016, reeled in $30 million in series A funding last year. In November, Vir Biotechnology announced it was initiating a phase 1/2 trial of its gene-silencing drug for hepatitis B, the first clinical candidate from its partnership with Alnylam.

Suggested Articles

Qiagen is collaborating with Ares Genetics to develop new bioinformatics and assay solutions for research targeting antibiotic-resistant bacteria.

STA Pharmaceutical has signed an exclusive technology and marketing deal with Swiss biotech BioLingus.

Clinerion is partnering with Citeline to give clinical researchers a more comprehensive approach to making evidence-based decisions.